U.S. markets open in 2 hours 10 minutes
  • S&P Futures

    4,408.75
    -5.50 (-0.12%)
     
  • Dow Futures

    34,964.00
    -70.00 (-0.20%)
     
  • Nasdaq Futures

    15,121.00
    +3.25 (+0.02%)
     
  • Russell 2000 Futures

    2,206.40
    -7.00 (-0.32%)
     
  • Crude Oil

    72.02
    +0.11 (+0.15%)
     
  • Gold

    1,795.90
    -3.30 (-0.18%)
     
  • Silver

    25.17
    -0.15 (-0.60%)
     
  • EUR/USD

    1.1794
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.2760
    0.0000 (0.00%)
     
  • Vix

    18.41
    +1.21 (+7.03%)
     
  • GBP/USD

    1.3792
    -0.0032 (-0.23%)
     
  • USD/JPY

    110.1200
    -0.2550 (-0.23%)
     
  • BTC-USD

    37,629.29
    -931.44 (-2.42%)
     
  • CMC Crypto 200

    893.99
    -21.50 (-2.35%)
     
  • FTSE 100

    7,002.90
    -22.53 (-0.32%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA

·2 min read

Shares of Ardelyx, Inc. ARDX plummeted 73.9% following negative regulatory update related to its new drug application (“NDA”) seeking approval for lead pipeline candidate, tenapanor, as a treatment for hyperphosphatemia, an elevated level of serum phosphate in the blood, in patients with chronic kidney disease on dialysis.

The company announced that the FDA identified deficiencies in the NDA, which prevent discussion related to labeling and post-marketing requirements/commitments currently. Although the FDA did not provide specific details regarding the deficiencies, it noted that the size of the treatment effect and its clinical relevance was a key issue. Moreover, the FDA denied a request for a meeting made by the company to discuss the deficiencies.

The FDA also stated that the notification about deficiencies does not reflect its final decision related to the NDA.

We note that Ardelyx submitted the NDA supported by data from three successful pivotal studies. The company also had a discussion related to labeling with the FDA in April. The unexpected deficiency notification from the FDA significantly impacted investors’ sentiments. However, the FDA had extended the review period for tenapanor NDA in April by three months.

Shares of Ardelyx have declined 68.9% so far this year compared with the industry’s decrease of 11.9%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The company’s tenapanor is already approved as Ibsrela for treating irritable bowel syndrome with constipation (IBS-C) in adults.

However, we note that Ironwood Pharmaceuticals IRWD/AbbVie’s ABBV Linzess holds a strong position in the IBS-C segment. Bausch Health BHC has an IBS-C drug, Trulance, in its marketed portfolio. These drugs pose competition to Ibsrela.

Ardelyx is also developing another pipeline candidate, RDX013, as a treatment for hyperkalemia — a condition of elevated level of potassium in the blood. The company has an ongoing discovery program for a bicarbonate exchange inhibitor for the treatment of metabolic acidosis.

Ardelyx, Inc. Price

Ardelyx, Inc. Price
Ardelyx, Inc. Price

Ardelyx, Inc. price | Ardelyx, Inc. Quote

Zacks Rank

Ardelyx currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

Ardelyx, Inc. (ARDX) : Free Stock Analysis Report

Bausch Health Cos Inc. (BHC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research